[go: up one dir, main page]

ES2107049T3 - Cianoguanidinas como bloqueadores de canales de potasio. - Google Patents

Cianoguanidinas como bloqueadores de canales de potasio.

Info

Publication number
ES2107049T3
ES2107049T3 ES93917262T ES93917262T ES2107049T3 ES 2107049 T3 ES2107049 T3 ES 2107049T3 ES 93917262 T ES93917262 T ES 93917262T ES 93917262 T ES93917262 T ES 93917262T ES 2107049 T3 ES2107049 T3 ES 2107049T3
Authority
ES
Spain
Prior art keywords
alkyl
hydrogen
channel blockers
potassium channel
cyanoguanidines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93917262T
Other languages
English (en)
Inventor
Stephen J Humphrey
Kaushik D Meisheri
James H Ludens
Jackson B Hester Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn Co
Application granted granted Critical
Publication of ES2107049T3 publication Critical patent/ES2107049T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE PRESENTAN COMPUESTOS DE CIANOGUANIDINA DE LA FORMULA (I) Y SUS SALES DE ADICION ACIDA FARMACOLOGICAMENTE ACEPTABLES EN DONDE R1 ES HIDROGENO O METILO; R2 ES ALQUILO C1-C6; ALQUENILO C2-C6; ALQUINILO C2-C6, ALQUINILO C2-C6, CICLOALQUILO C3-C5, CICLOALQUENILO(C3-C5 HIDROXIMETILO), METOXIALQUILO C1-C5 O R1 Y R2 SE COMBINAN PARA FORMAR UN ANILLO CARBOXILICO C3-C6; R3 Y R4 SE SELECCIONAN CADA UNA INDEPENDIENTEMENTE DE HIDROGENO, ALQUILO C1-C4, D, CL, BR, I O CF3; R5 ES HIDROGENO, F O CL; R6 ES HIDROGENO, -NH2, -NHCH3-, -NHC2H5, NHCH(CH3)2, -N(CH3)2, -N(C2H5)2, NH(CH2)M, -O-ALQUILO C1-C3 (EN DONDE M ES 2 O 3), -NHC(O)ALQUILO C1-C3, CL O BR; Y N ES 0 O 1. LOS COMPUESTOS DE LA FORMULA (I) SON BLOQUEADORES DEL CANAL DE POTASIO UTILES EN EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES TALES COMO EL FALLO CARDIACO CONGESTIVO Y LA HIPERTENSION Y TAMBIEN COMO DIURETICOS.
ES93917262T 1992-08-13 1993-07-21 Cianoguanidinas como bloqueadores de canales de potasio. Expired - Lifetime ES2107049T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92979592A 1992-08-13 1992-08-13

Publications (1)

Publication Number Publication Date
ES2107049T3 true ES2107049T3 (es) 1997-11-16

Family

ID=25458467

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93917262T Expired - Lifetime ES2107049T3 (es) 1992-08-13 1993-07-21 Cianoguanidinas como bloqueadores de canales de potasio.

Country Status (16)

Country Link
US (1) US5567722A (es)
EP (1) EP0655057B1 (es)
JP (1) JPH08500111A (es)
CN (1) CN1039997C (es)
AT (1) ATE158279T1 (es)
AU (2) AU4530693A (es)
DE (1) DE69314041T2 (es)
DK (1) DK0655057T3 (es)
ES (1) ES2107049T3 (es)
GR (1) GR3025640T3 (es)
IL (1) IL106641A (es)
MX (1) MX9304882A (es)
MY (1) MY110826A (es)
TW (1) TW223017B (es)
WO (2) WO1994004499A1 (es)
ZA (1) ZA935619B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2116726T3 (es) * 1994-01-28 1998-07-16 Upjohn Co Cianoguanidinas utilizadas como bloqueadores del canal k.
AUPN193095A0 (en) * 1995-03-24 1995-04-27 Polychip Pharmaceuticals Pty Ltd Potassium ion channel blockers
AR008290A1 (es) * 1996-08-15 1999-12-29 Smithkline Beecham Corp Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios.
WO1998006398A1 (en) * 1996-08-15 1998-02-19 Smithkline Beecham Corporation Il-8 receptor antagonists
EP1917244A2 (de) 2005-08-24 2008-05-07 Abbott GmbH & Co. KG Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
CN113683535B (zh) * 2020-05-18 2022-08-30 中国药科大学 含氰胍结构的化合物及其制备方法与用途
CN112042664B (zh) * 2020-09-18 2022-06-10 广州古神生物科技有限公司 防霉抗菌剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1489879A (en) * 1974-12-20 1977-10-26 Leo Pharm Prod Ltd N'-cyano-n'-3-pyridylguanidines
NL8000869A (nl) * 1979-02-16 1980-08-19 Eisai Co Ltd Cyanoguanidine-derivaten en werkwijze voor de bereiding daarvan.
JPH01166119A (ja) * 1987-12-23 1989-06-30 Hitachi Ltd データ入力装置の制御方式
NZ229828A (en) * 1988-08-09 1992-03-26 Squibb & Sons Inc Aryl cyanoguanidine derivatives and pharmaceutical compositions
AU623217B2 (en) * 1989-02-03 1992-05-07 Eli Lilly And Company (-)-n"-cyano-n-3-pyridyl-n'-1,2,2-trimethyl- propylguanidine, a process for preparing the compound, and use of the compound as a medicament
US5006523A (en) * 1989-10-26 1991-04-09 E. R. Squibb & Sons, Inc. Antiarrhythmic agents: aryl cyanoguanidine potassium channel blockers

Also Published As

Publication number Publication date
JPH08500111A (ja) 1996-01-09
DK0655057T3 (da) 1998-04-14
EP0655057B1 (en) 1997-09-17
WO1994004499A1 (en) 1994-03-03
DE69314041D1 (de) 1997-10-23
ZA935619B (en) 1995-02-03
US5567722A (en) 1996-10-22
CN1039997C (zh) 1998-09-30
AU4530693A (en) 1994-03-15
DE69314041T2 (de) 1998-02-05
IL106641A0 (en) 1993-12-08
EP0655057A1 (en) 1995-05-31
TW223017B (es) 1994-05-01
ATE158279T1 (de) 1997-10-15
IL106641A (en) 2001-01-11
WO1994004500A1 (en) 1994-03-03
CN1090575A (zh) 1994-08-10
MX9304882A (es) 1994-07-29
GR3025640T3 (en) 1998-03-31
MY110826A (en) 1999-05-31
AU4683193A (en) 1994-03-15

Similar Documents

Publication Publication Date Title
SG159380A1 (en) Heteroaryl compounds useful as inhibitors of gsk-3
NO20013379L (no) 4-okso-1,4-dihydro-3-kinolinkarboksamider som antivirusmidler
MA26996A1 (fr) Derives de glutaramide a substituant n-phenpropylcyclopentyle, servant d'inhibiteurs de nep pour un trouble d'eveil sexuel feminin
GR3006247T3 (es)
KR960702460A (ko) 티아졸리딘디온 및 이것을 함유하는 약제(new thiazolidindiones and drugs containing them)
DK0759919T3 (da) Azolidindioner som antihyperglykæmiske midler
ES2107049T3 (es) Cianoguanidinas como bloqueadores de canales de potasio.
TW429255B (en) Pyrazine compounds having treatment of central nervous system diseases and disorders
SE8406302D0 (sv) New aminoguanidine derivatives and a process for the preparation thereof
JPS5750989A (en) Imidazole compound
AU7615794A (en) Derivatives of 2-amino-1,2,3,4-tetrahydronaphthalene active on the cardiovascular system
ES2093091T3 (es) Derivado de glutation.
ATE106400T1 (de) Substituierte 3h-indole, verfahren zu ihrer herstellung sowie arzneimittel.
MY131544A (en) Fluorinated 4-aminoandrostadienone derivatives and process for their preparation
ES2152319T3 (es) Derivado del benceno util contra isquemias.
GR3029737T3 (en) Pyrimidine cyanoguanidines as k-channel blockers
ATE42295T1 (de) Penem-derivate, verfahren zu deren herstellung, ihre verwendung und pharmazeutische zusammensetzungen.
DK1049672T3 (da) Azetidincarboxamid-derivater til behandling af CNS-lidelser
DE69502584D1 (de) Cyanoguanidine als k-kanal-blocker
CA2272098A1 (en) Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
MX9305918A (es) Derivados de n-(2-amino-2-oxoetil)butanodiamida inhibidores de la renina procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
PE16199A1 (es) Compuestos de 2-imidazolinilaminobenzotiazol utiles como agonistas de alfa-2 adrenoreceptores
EP0982029A4 (en) PREVENTIVE / MEDICINE FOR ARTERIOSCLEROSIS
DK1049670T3 (da) Azetidincarboxamidderivater til behandling af CNS-lidelser
SE7713864L (sv) Nortropinkarbazatderivat och forfarande for framstellning av dem

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 655057

Country of ref document: ES